Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-08-16
2011-08-16
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S234000
Reexamination Certificate
active
07998993
ABSTRACT:
Compounds of formula (I)wherein R1, R2, R4, and W are defined in the description are TRPV 1 antagonists with CNS penetration. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
REFERENCES:
patent: 5151440 (1992-09-01), Gluchowski
patent: 2006/0281799 (2006-12-01), Gomtsyan et al.
patent: WO 2006/122250 (2006-11-01), None
patent: WO-2006122250 (2006-11-01), None
Ettmayer et al. “Lessons Learned from Marketed and Investigational Prodrugs.” J. Med. Chem., (2004), 47(10): 2393-2404.
Stella, Valentino. “Prodrugs as therapeutics.” Expert Opin. Ther. Patents (2004), 14(3): 277-280.
Testa, Bernard. “Prodrug research: futile or fertile?” Biochemical Pharmacology, 68 (2004): 2097-2106.
Wolff et al. Burger's Medicinal Chemistry and Drug Discovery. 5th ed. vol. 1: Principles and Practice (1995). pp. 975-977.
Berge, S.M. et al., “Journal of Pharmaceutical Sciences, Pharmaceutical Salts,” J Pharmaceutical Sciences, 1977, 1-19, vol. 66.
Caterina et al., “Impaired Nociception and Pain Sensation in Mice Lacking the Capsaicin Receptor,” Science, 2000, 306-313, vol. 288.
Caterina et al., “The Vanilloid Receptor: A Molecular Gateway to the Pain Pathway,” Annu Rev Neurosci, 2001, 487-517, vol. 24.
Caterina M.J. et al., “The Capsaicin Receptor: A Heat-Activated Ion Channel in the Pain Pathway,” (Binary/Image), 1997, 816-824, vol. 389.
Cui M et al., “TRPV1 Receptors in the CNS Play a Key Role in Broad-Spectrum Analgesia of TRPV1 Antagonists,” The Journal of Neuroscience, 2006, vol. 26 (37), pp. 9385-9393.
Davis et al., “Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia,” (Binary/Image), 2000, 183-187, vol. 405.
Fowler, C. “Intravesical Treatment of Overactive Bladder,” Urology, 2000, 60-64, vol. 55.
Greene, T.W. et al., “Protective Groups in Organic Synthesis”, 1999, 3 rd Ed, 494-653.
Hayes et al., “Cloning and Functional Expression of a Human Orthologue of Rat Vanilloid Receptor-1,” (Binary/Image), 2000, 205-215, vol. 88.
Marsch R, Foeller E, Rammes G, et al., “Reduced anxiety, conditioned fear, and hippocampal long-term potentiation in transient receptor potential vanilloid type 1 receptor-deficient mice,” J Neurosci, 2007, 0832-09-01, 27/4.
Mezey, Eva et al., “Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human,” Neurobiology, 2000, vol. 97 (7), pp. 3655-3660.
Nolano et al., “Topical Capsaicin in Humans: Parallel Loss of Epidermal Nerve Fibers and Pain Sensation,” (Binary/Image), 1999, 135-145, vol. 81.
Prescott et al., Methods in Cell Biology, 1976, vol. XIV, 33, Academic Press.
Roberts c. Jennifer et.al, “[3H]Resiniferatoxin autoradiography in the CNS of wild-type and TRPV1 null mice defines TRPV1 (VR-1) protein distribution,” Brain Research, 2004, vol. 995, pp. 176-183.
Szabo T. et al., “Pharmacological characterization of vanilloid receptor located in the brain,” Molecular Brain Research, 2002, vol. 98, pp. 51-57 , Elsevier Science.
Tzavara ET, Li DL, Moutsimilli L, et al., “Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdoaminergia-related hyperactivity: therapeutic implications,” Biol Psychiatry, 2006, 508-15, 59/6.
Westaway S.M., “The potential of transient receptor potential vanilloid type 1 channel modulators for the treatment of pain, XP002452089,” Journal of Medicinal Chemistry, vol. 50, pp. 2589-2596, 2007.
Bayburt Erol K.
Daanen Jerome F.
DiDomenico, Jr. Stanley
Gomtsyan Arthur
Koenig John R.
Abbott Laboratories
Anderson Rebecca
Mueller Lisa V.
Otton Alicia L
Polsinelli Shughart PC
LandOfFree
TRPV1 antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with TRPV1 antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and TRPV1 antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2721989